Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Generic Oncology Sterile Injectable Market – Insights

Generic oncology sterile injectables are biologics that have the same active ingredients as that of the branded version, with only the inactive contents of the drugs being different. Manufacturers of generic sterile injectables have to adhere to regulations by the U.S. Food and Drug Administration (FDA) for the development of these injectables, which are equivalent to that of branded counterparts. These generic oncology sterile injectables are used for the treatment of various types of cancer including breast, prostate, colorectal, melanoma, lung, and bronchus. These injectables are available at low prices and therefore, are widely preferred over branded drugs.

Furthermore, R&D for generic drugs require less capital, which increase competition to enter into generic oncology sterile injectable market as soon as the patent for branded injectables expire. However, the emergence of biosimilars have increased in the recent past. After Europe, increasing number of biosimilars are approved in the U.S. market. This is expected to drive growth of the generic oncology sterile injectable market growth during the forecast period.

The global generic oncology sterile injectable market size is estimated to be valued at US$ 11,496.7 million in 2019 and is expected to witness a CAGR of 11.5% over the forecast period (2019 – 2027).

Global Generic Oncology Sterile Injectable Market Share (%) Analysis, By Product Type, 2019

Generic Oncology Sterile Injectable  | Coherent Market Insights

Source: Coherent Market Insights Analysis (2020)

Increasing launches of drugs is expected to drive growth of the global generic oncology sterile injectable market

Manufacturers in the U.S. are focusing on launching new products to offer low cost treatment to patients. For instance, in November, 2017, Mylan N.V. launched Clofarabine Injection (20 mg/20 mL (1 mg/mL) Single-Dose Vials) following the U.S. Food and Drug Administration approval in the U.S. market. Clofarabine is a generic version of Genzyme's Clolar, which is used for the treatment of refractory acute lymphoblastic leukemia in patients aged 1 year to 21 years.

Global Generic Oncology Sterile Injectable Market – Restraints

Stringent rules and regulations for manufacturing of sterile oncology injectables, high quality and care required during manufacturing, challenges in storage, packaging, and distribution of oncology sterile injectable are factors restraining the global generic oncology sterile injectable market growth.

Global Generic Oncology Sterile Injectable Market - Regional Insights

On the basis of region, the global generic oncology sterile injectable market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America holds dominant position in the global generic oncology sterile injectable market, owing to increasing launches of products in the U.S. For instance, in September 2019, Mylan N.V. launched Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose prefilled syringe, a generic version of AstraZeneca's Faslodex Injection, for the treatment of advanced breast cancer in the U.S.

Asia Pacific is the fastest growing region in the global generic oncology sterile injectable market, owing to increasing initiatives taken by key players in this region. For instance, in 2017, Alembic Pharmaceutical Limited launched manufacturing facility in India to manufacture generic oncology products for international market.

Global Generic Oncology Sterile Injectable Market Value (US$ Mn) & Y-o-Y Growth (%), 2016-2027

Generic Oncology Sterile Injectable  | Coherent Market Insights

 Source: Coherent Market Insights Analysis (2020)

Global Generic Oncology Sterile Injectable Market - Competitive Landscape

Key players operating in the global generic oncology sterile injectable market include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.

Generic oncology sterile injectables are used for the treatment of various types of cancers such as ovarian, breast, and lung. Generic oncology sterile injectables products are relatively cheaper than branded counterparts. Treatment cost is a major concern for cancer patients, especially in emerging economies such as India, Brazil, and China. Therefore, governments of such countries are taking efforts to reduce cost of medications and increase its accessibility. For instance, the National Pharmaceutical Pricing Authority (NPPA) of India reduced the prices of few cancer products by 86% in March 2017.

Generic oncology sterile injectables have a huge potential in such countries, where patient population is high; however, spending power is relatively low. Furthermore, patent expiry of product is expected to fuel growth of the generic oncology sterile injectables market during the forecast period. The emergence of biosimilars have also impacted the growth of generics oncology sterile products. For instance, according to the Journal of Generics and Biosimilars Initiative, 2017, biosimilars have a major share in Europe and in the U.S. since 2013 and 2015, respectively, and the share of biosimilars is expected to increase significantly in the biologicals market. This is expected to eventually boost growth of the generic oncology sterile injectable market.

Market Dynamics

Generic oncology sterile injectables market is gaining significant traction due to rising prevalence of cancer cases. For instance, according to the World Health Organization, in 2018, around 18.1 million new cases of cancer and 9.6 million deaths were reported, globally.

However, lack of awareness amongst the people in low-income and middle-income countries regarding cervical cancer is expected to hinder growth of the generic oncology sterile injectables market during the forecast period. Cervical cancer is one of the most common cancers among women of reproductive age in low-income and middle-income countries. For instance, according to The International Agency for Research on Cancer’s (IARC) report of 2013, cervical cancer is mostly prevalent in low-income countries of sub-Saharan Africa.

Key features of the study:

  • This report provides in-depth analysis of the global generic oncology sterile injectable market, market size (US$ Mn), and compound annual growth rate (CAGR (%) for the forecast period, 2019-2027, considering 2018 as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
  • It profiles key players in the global generic oncology sterile injectable market based on the following parameters: company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
  • Key players covered as a part of this study include Eli Lilly & Company, Biocon Ltd., Baxter International Inc., Hikma Pharmaceuticals PLC, Mylan N.V., Sandoz International GmbH, Teva Pharmaceutical Industries Ltd., and Pfizer Inc.
  • Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
  • The global generic oncology sterile injectable market report caters to various stakeholders in this industry, which include investors, product manufacturers, distributors, and suppliers of generic oncology sterile injectable market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

  • Global Generic Oncology Sterile Injectable Market, by Product Type:
    • Chemotherapy
      • Alkylating agents
      • Antimetabolites
      • Plant Alkaloids
      • Antitumor Antibiotics
      • Others
    • Monoclonal Antibodies
    • Cytokines
    • Peptide Hormones
  • Global Generic Oncology Sterile Injectable Market, by Disease Indication:
    • Ovarian Cancer
    • Breast Cancer
    • Lung Cancer
    • Pancreatic Cancer
    • Others
  • Global Generic Oncology Sterile Injectable Market, by Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Generic Oncology Sterile Injectable Market, by Region:
    • North America
      • By Country:
        • U.S.
        • Canada
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Europe
      • By Country:
        • U.K.
        • Germany
        • Italy
        • Spain
        • France
        • Russia
        • Rest of Europe
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Asia Pacific
      • By Country:
        • Australia
        • India
        • China
        • Japan
        • ASEAN
        • South Korea
        • Rest of Asia Pacific
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Latin America
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Middle East
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
    • Africa
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
      • By Product Type:
        • Chemotherapy
          • Alkylating agents
          • Antimetabolites
          • Plant Alkaloids
          • Antitumor Antibiotics
          • Others
        • Monoclonal Antibodies
        • Cytokines
        • Peptide Hormones
      • By Disease Indication:
        • Ovarian Cancer
        • Breast Cancer
        • Lung Cancer
        • Pancreatic Cancer
        • Others
      • By Distribution Channel:
        • Hospital Pharmacies
        • Retail Pharmacies
        • Online Pharmacies
  • Company Profiles
    • Eli Lilly & Company*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Recent Highlights
      • Strategies
    • Biocon Ltd.
    • Baxter International Inc.
    • Hikma Pharmaceuticals PLC
    • Mylan N.V.
    • Sandoz International GmbH
    • Teva Pharmaceutical Industries Ltd.
    • Pfizer Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Overview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Product Type
      • Market Snippet, By Disease Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Market Trends
    • Key Developments
    • Regulatory Scenario
    • Industry Trend
    • Merger and Acquisitions
    • New Product Approvals/Launch
    • Promotion and Marketing Initiatives
    • PEST Analysis
  4. Global Generic Oncology Sterile Injectable Market, By Product Type, 2016 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Chemotherapy           
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Alkylating agents
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Antimetabolites
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Plant Alkaloids
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Antitumor Antibiotics
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
        • Others
          • Introduction
          • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Cytokines
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Peptide Hormones
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  5. Global Generic Oncology Sterile Injectable Market, By Disease Indication, 2016– 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Ovarian Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Pancreatic Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  6. Global Generic Oncology Sterile Injectable Market, By Distribution Channel, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Million)
  7. Global Generic Oncology Sterile Injectable Market, By Region, 2019 – 2027, (US$ Million)
    • Introduction
      • Market Share Analysis, By Region, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, By Region, 2017 – 2026
      • Regional Trends
    • North America
      • Market Size and Forecast, By Product Type, 2016 – 2027 , (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.S.
        • Canada
    • Europe
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • China
        • Japan
        • India
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Million)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Product Type, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Disease Indication, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Million)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Million)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Eli Lilly & Company.*
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Biocon Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Baxter International Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Hikma Pharmaceuticals PLC
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Mylan N.V.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Sandoz International GmbH
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Teva Pharmaceutical Industries Ltd
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
      • Pfizer Inc.
        • Company Overview
        • Product Portfolio
        • Financial Performance
        • Recent Highlights
        • Strategies
    • Analyst Views
  9. Section
    • References
    • Research Methodology         
    • About Us and Sales Contact

*Browse 35 market data tables and 39 figures on “Generic Oncology Sterile Injectable Market” - Global forecast to 2027”

Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner